York County-based Unilife Corp. said today it has signed an agreement with a U.S. pharmaceutical company for Unilife's EZMix dual-chamber syringe, according to a news release.
Unilife anticipates generating revenue of up to $110 million during the 15-year customization and commercial supply agreement, the release stated.
The identity of the customer was not released for commercial purposes and because of confidentiality provisions in the agreement.
Unilife is a developer and commercial supplier of injectable drug delivery systems. Shares are traded in the United States on the Nasdaq under the ticker symbol UNIS.